Real‐World Utilization Pattern and Outcomes of Letermovir in Adult Cytomegalovirus‐Seropositive Allogeneic Hematopoietic Cell Transplant Recipients: An International Retrospective Study From the Infectious Diseases Working Party of EBMT
Transplant Infectious Disease · 2026
DOI: 10.1111/tid.70196 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Transplant Infectious Disease, 2026. Verfasst von Jan Styczynski und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation, Acetates, Quinazolines. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction
The objective of this study was to analyze outcomes associated with letermovir for CMV primary prophylaxis in adult CMV‐seropositive allo‐HCT recipients in a multicenter real‐world scenario.
Methods
This retrospective real‐world international study involved 481 adults undergoing allo‐HCT between 2018 and 2020 who received letermovir for primary prophylaxis. Outcomes included clinically significant CMV infection (csCMVi), graft‐versus‐host disease, opportunistic infections, all‐cause mortality, hospitalizations, and ICU admissions. The median follow‐up was 33.8 months.
Results
The median start time of letermovir was 3 days after transplant, with a median duration of prophylaxis of 100 days. The cumulative incidence of csCMVi was 2.7% (95% CI = 1.5–4.5) at 3 months, 13.1% (95% CI = 10.3–16.3) at 6 months, and 17.1% (95% CI = 13.9–20.6) at 12 months. The median time from HCT to csCMVi was 142 days. In multivariate analysis, four factors contributed to development of csCMVi: reduced‐intensity conditioning (HR = 1.90; 95% CI = 1.17–3.08; p = 0.009), peripheral blood as cell source (HR = 2.92; 95% CI = 1.00–8.50; p = 0.0495), pretransplant CMV serostatus D−/R+ (HR = 2.24; 95% CI = 1.42–3.53; p = 0.0005), use of alemtuzumab (HR = 3.91; 95% CI = 1.60–9.59; p = 0.003). There was no difference in the cumulative incidence of csCMVi in the first 100 days between patients who started letermovir ≤ 5 versus > 5 days after transplant. Factors adversely contributing to overall survival: age as a continuous variable, 10‐year effect (HR = 1.23; 95% CI = 1.08–1.41; p = 0.002), patient male sex (HR = 1.48; 95% CI = 1.02–2.13; p = 0.038), status > CR1 of disease at transplant (HR = 1.97; 95% CI = 1.36–2.85; p = 0.0004), PB as stem cell source (HR = 1.81; 95% CI = 1.04–3.15; p = 0.04), acute leukemia diagnosis (HR = 1.61; 95% CI = 1.10–2.34; p = 0.01), CMV high‐risk patients (HR = 1.52; 95% CI = 1.02–2.27; p = 0.04).
Conclusions
An analysis of real‐world use of letermovir in CMV prophylaxis after allo‐HCT showed a low incidence of csCMVi compared to previously published information.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
- EBMT Leiden Study Unit, Leiden, the Netherlands.
- Karolinska University Hospital Huddinge, Karolinska Comprehensive Cancer Center, Karolinska Institutet, Stockholm, Sweden.
- Faculty of Medicine, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel.
- USD Trapianti di Midollo, Adulti, Brescia, Italy.
- BMT Unit, Saint-Louis Hospital, Paris, France.
ORCID-Profile: Jan Styczynski, Ilaria Cutini, Patrizia Chiusolo, Leotta Salvatore, Rafael de la Camara
Zitieren
APA
Styczynski, J., Tridello, G., Knelange, N., Wendel, L., Ljungman, P., Averbuch, D., Russo, D., Xhaard, A., Dominietto, A., Onida, F., Beauvais, D., Kempshall, E., Cutini, I., Chiusolo, P., Platzbecker, U., Carella, A. M., Ferreri, A., Mico, M. C., Kraus, S., …, & de la Camara, R. (2026). Real‐World Utilization Pattern and Outcomes of Letermovir in Adult Cytomegalovirus‐Seropositive Allogeneic Hematopoietic Cell Transplant Recipients: An International Retrospective Study From the Infectious Diseases Working Party of EBMT. Transplant Infectious Disease. https://doi.org/10.1111/tid.70196
Vancouver
Styczynski J, Tridello G, Knelange N, Wendel L, Ljungman P, Averbuch D, et al. Real‐World Utilization Pattern and Outcomes of Letermovir in Adult Cytomegalovirus‐Seropositive Allogeneic Hematopoietic Cell Transplant Recipients: An International Retrospective Study From the Infectious Diseases Working Party of EBMT. Transplant Infectious Disease. 2026. doi:10.1111/tid.70196
BibTeX
@article{Styczynski2026,
author = {Styczynski, Jan and Tridello, Gloria and Knelange, Nina and Wendel, Lotus and Ljungman, Per and Averbuch, Dina and Russo, Domenico and Xhaard, Alienor and Dominietto, Alida and Onida, Francesco and Beauvais, David and Kempshall, Emma and Cutini, Ilaria and Chiusolo, Patrizia and Platzbecker, Uwe and Carella, Angelo Michele and Ferreri, Annie and Mico, Maria Catarina and Kraus, Sabrina and Mehra, Varun and Salvatore, Leotta and Federico, Vincenzo and Tang, Yuexin and Kolobova, Irina and Beyer, Andrew P and Patel, Deepa and de la Camara, Rafael},
title = {Real‐World Utilization Pattern and Outcomes of Letermovir in Adult Cytomegalovirus‐Seropositive Allogeneic Hematopoietic Cell Transplant Recipients: An International Retrospective Study From the Infectious Diseases Working Party of EBMT},
journal = {Transplant Infectious Disease},
year = {2026},
doi = {10.1111/tid.70196}
}
EUVIMED